EZZ.ASX: Appendix 4E - Preliminary Final Report

Appendix 4E - Preliminary Final Report

Stock	EZZ Life Science Holdings Ltd (EZZ.ASX)
Release Time	29 Aug 2025, 4:16 p.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

EZZ Life Science Reports FY2025 Results

Key Points

Revenues up 0.65% to $66.87 million
Profit down 3.36% to $6.73 million
Dividends of 4 cents per share paid

Full Summary

EZZ Life Science Holdings Ltd has released its preliminary financial results for the year ended 30 June 2025. The company reported revenues of $66,873,691, up 0.65% from the previous year. Profit after tax attributable to the owners of EZZ Life Science Holdings Limited was $6,730,441, down 3.36% from the previous year. The directors noted that Underlying Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) and Underlying EBIT were used to reflect the core earnings of the consolidated entity. The company's net assets increased from $21,322,838 as at 30 June 2024 to $28,085,315 as at 30 June 2025, with share capital increasing due to the issue of shares via employee incentive schemes and the exercise of performance rights. EZZ Life Science Holdings Ltd paid a final dividend of 2 cents per share on 9 December 2024 and an interim dividend of 2 cents per share on 17 June 2025, both fully franked.